Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, says that although supply-chain difficulties brought on by the COVID-19 pandemic appear to be easing, “the significant rise in demand for medicines alongside other challenges in the operating environment would mean that manufacturers will have to deal with new and different issues to ensure that patients are able to access their medicines.”
Due to the coronavirus outbreak, supply-chain disruption has become a concern, whether due to closed borders in Europe or elsewhere, or the reduction of long-haul
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?